Hua Medicine confirms patient enrollment for study of diabetes drug
Category: #health  By Mateen Dalal  Date: 2019-03-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Hua Medicine confirms patient enrollment for study of diabetes drug

Shanghai-based drug development firm Hua Medicine, which focuses on developing global first-in-class oral drug for treating Type 2 diabetes, has recently announced that it has completed patient enrollment for a Phase III monotherapy trial of dorzagliatin (HMS5552). The company is expecting to release topline results from the study in the fourth quarter of 2019.

CEO of Hua Medicine, Dr. Li Chen, was quoted saying that this milestone takes the company one step closer to bringing dorzagliatin to the Chinese market, which consists of 120 million Type 2 diabetics.  The novel, first-in-class drug would be a 3rd generation T2D drug, since it holds the potential to stop the progression of T2D, something which existing drugs have not been able to achieve, he said.

Dr. Chen added that the protocol follows the company’s Phase II study design, which provided strong efficacy and safety data along with promising disease modifying effects. Hua Medicine informed that the Phase III monotherapy registration trial would target patients who are drug naïve, which will position dorzagliatin as a first-line therapy. The trial is a placebo-controlled, double-blind study with patients being randomized 2:1 for receiving either placebo or dorzagliatin.

The clinical study would apparently evaluate the safety and efficacy of dorzagliatin with 24-week long double-blinded treatment plus 28 weeks of open-label treatment and follow-up. The study will be conducted at 40 clinical sites all over China, the company mentioned.

For the record, first-in-class glucokinase activator (GKA) dorzagliatin, is a drug designed for controlling diabetes’ progressive degenerative nature by restoring glucose homeostasis in Type 2 diabetics. Hua Medicine reportedly in-licensed dorzagliatin’s global rights from Roche.

Essentially, dorzagliatin has the potential to repair the impaired glucose homeostasis state in Type 2 diabetics by tackling the defect of the glucose sensor function of glucokinase, Hua Medicine stated. This can make the drug a first line standard of care therapy for treating patients with Type 2 Diabetes, or even as a cornerstone therapy to be applied in combination with existing anti-diabetes drugs which are approved.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
By Mateen Dalal

Telenor Group, an international provider of tele, data and media communication services, has reportedly agreed to sell its 51% stake in Myanmar's Wave Money, a provider of digital payment service, for $53 million to Yoma MFS Holdings, a subsidiar...

Alkem to launch state-of-the-art technology to treat DFU in India
Alkem to launch state-of-the-art technology to treat DFU in India
By Mateen Dalal

Alkem Laboratories Ltd. (Alkem), an Indian multinational pharmaceutical company, has reportedly launched a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on an innovative technology of...

Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
By Mateen Dalal

According to Andy Aldridge, Bank of America Spokesperson, the financial institutiThe Bank of America Corporation, an American multinational investment bank and financial services, has now opened up a new place for clients in North Bethlehem who are l...